studies

1058A AASLD ABSTRACTS HEPATOLOGY, October, 2015
The following authors have nothing to disclose: Chiara Rocha, M. Isabel Fiel, Erin
H. Doyle, Nicolas Goossens, Yujin Hoshida, Myron E. Schwartz
1743
Treating HCV patients on the LT waiting list with Sofosbuvir
plus Ribavirin is associated with clinical benefits
and allows for safe assignement of older grafts to LT
recipients
Maria Francesca Donato 1 , Daniele E. Dondossola 2 , Federica Malinverno
1 , Sara Monico 1 , Cristina Rigamonti 1 , Lucio Caccamo 2 ,
Alessio Aghemo 1 , Margherita Cavenago 2 , Giovanna Lunghi 3 ,
Barbara B. Antonelli 2 , Giorgio Rossi 2 , Massimo Colombo 1 ; 1 Division
of Gastroenterology and Hepatology, Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico, University of Milan,
Milan, Italy; 2 Division of Surgery and Liver Transplant, Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;
3 Department of Clinical Chemistry and Microbiology, Bacteriology
and Virology Units, Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milan, Italy
Background and aim SOF/R treatment in HCV(+) cirrhotics
on the liver transplant (LT) waiting list is a major breakthrough
since HCV-graft recurrence might be prevented in 95% of
recipients with >4 weeks viral suppression before transplant.
We aimed to evaluate the clinical-virological outcome of
pre-LT SOF/R regimen in patients who stopped treatment at
LT because they were HCV-RNA undetectable for >4 weeks
(SOF-pT) comparing them to patients who received bridging
pre to post-transplant therapy (SOF-bppT) for lack of 4 weeks
of HCV RNA undetectability at LT. Methods From July 2014
an Italian compassionate use program by Gilead-Sciences
endorsed by AISF-AIFA allowed us to treat all HCV consecutive
transplant candidates at our Center with SOF 400 mg/day +
R 200-1000 mg/day. Treated patients were compared with
19 previously transplanted HCV-recipients (January-June 2014)
who were left untreated before LT. Results 30 HCV-LT candidates
received SOF/R pre-LT: 16 received LT while 13 are still
in LT list and 1 died. 9/16 (56%) received SOF-pT whereas 7
(44%) received SOF-bppT for a total duration of 24 weeks. The
2 groups of SOF-treated patients were similar for sex, recipient
age, donor age, HCV genotype or pretreatment viremia,
MELD/Child and type of immunosuppression. The duration of
SOF-therapy before LT was shorter in SOF-b-ppT compared to
SOF-pT (32 vs 85 days, respectively; p